Jim Cramer and Hedge Funds Agree on These 5 Stocks

In this article, we discuss the 5 stocks that Jim Cramer and hedge funds agree on. If you want to read about some more stocks that Jim Cramer and hedge funds agree on, go directly to Jim Cramer and Hedge Funds Agree on These 10 Stocks. 

5. BioNTech SE (NASDAQ:BNTX)

Number of Hedge Fund Holders in Q1 2022: 29

Number of Hedge Fund Holders in Q4 2021: 27

BioNTech SE (NASDAQ:BNTX) is a biotech firm based in Germany. During the Lightning Round segment of his show on May 18, Cramer, while answering an audience question about his thoughts on the biotech company, said that he “liked BioNTech”. Cramer noted that he thinks that one day the Chinese government might go for a vaccine from Germany instead of the United States and that is why he was bullish on the firm. 

On April 12, HC Wainwright analyst Robert Burns maintained a Buy rating on BioNTech SE (NASDAQ:BNTX) stock and lowered the price target to $298 from $339, citing “guidance and a pulling forward in his discounted cash flow-based valuation” for the updated target. 

At the end of the first quarter of 2022, 29 hedge funds in the database of Insider Monkey held stakes worth $409 million in BioNTech SE (NASDAQ:BNTX), up from 27 the preceding quarter worth $644 million.

In its Q3 2021 investor letter, Baron Funds, an asset management firm, highlighted a few stocks and BioNTech SE (NASDAQ:BNTX) was one of them. Here is what the fund said:

“BioNTech SE (NASDAQ:BNTX) is a leader in the emerging field of mRNA drugs, with additional programs in engineered cell therapies, antibodies, and immunomodulators. Shares performed well for the quarter. The COVID-19 vaccine rollout continues with the addition of a booster shot, and we believe the pandemic has been a strong proof point of the speed and efficacy of the mRNA platform. Beyond vaccines, we think BioNTech SE (NASDAQ:BNTX) has potential to disrupt the biopharmaceutical space with a pipeline spanning oncology, infectious diseases, and rare diseases.”